Clinical Trials for Gallbladder Cancer

A Phase IIa Clinical Trial of First-Line Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for Advanced Biliary Tract Cancers With FGFR2 Alterations

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic biliary tract cancer harboring an FGFR2 fusion, rearrangement, or other activating FGFR alteration receive first-line alternating blocks of gemcitabine/cisplatin plus the PD-L1 inhibitor durvalumab and oral pemigatinib, an FGFR1–3 inhibitor. Prior FGFR-targeted therapy is not allowed.

ClinicalTrials.gov ID: NCT07780838

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated unresectable or metastatic KRAS G12D–mutated solid tumors are eligible for dose escalation; dose expansion is limited to pancreatic ductal adenocarcinoma after at least one prior systemic therapy. All receive IV ARV-806, an investigational PROTAC designed to degrade mutant KRAS G12D, weekly or every two weeks.

ClinicalTrials.gov ID: NCT07023731

Safety of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Biliary Tract Cancer Patients With Peritoneal Metastases

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with untreated advanced biliary tract cancer (cholangiocarcinoma or gallbladder) and peritoneal metastases, ECOG 0–1, receive standard gemcitabine/cisplatin plus intraperitoneal nab-paclitaxel delivered via PIPAC at specified cycles. Nab-paclitaxel (albumin-bound paclitaxel; microtubule inhibitor) is aerosolized under pressure laparoscopically to enhance peritoneal penetration, with the study focused on safety and feasibility.

ClinicalTrials.gov ID: NCT05285358